State Of Clinical Trial Technology: The AI Inflection Point

Clinical trial operations are facing a decisive turning point as digital maturity and AI adoption diverge across research sites. While many organizations continue to rely on paper, email, and fragmented systems, a growing segment is proving what’s possible when digital infrastructure, integrated workflows, and disciplined change management are in place. These digitally mature sites are generating real‑time operational data, experimenting with AI in high‑effort tasks, and gaining measurable improvements in startup speed, staff efficiency, and financial performance.

Yet the industry is confronting a widening chasm. System sprawl, duplicative sponsor technology, and disconnected workflows remain major barriers, limiting visibility and slowing study execution. AI’s rapid rise only sharpens this divide: it accelerates progress for sites with connected data, while offering little value to those still mired in manual processes.
The white paper outlines the strategic imperatives for 2026: reduce dependence on paper and email, adopt flexible technology models, experiment intentionally with AI, and invest in persistent intelligence that accumulates insights across studies. These shifts signal a new era—one defined by predictive operations, real‑time oversight, and stronger alignment across sites, sponsors, and CROs.

Access the full report to understand where your organization stands and how to move forward with confidence.